Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 6
1999 3
2000 3
2001 3
2002 7
2003 2
2004 10
2005 9
2006 10
2007 15
2008 8
2009 9
2010 9
2011 13
2012 14
2013 8
2014 18
2015 11
2016 12
2017 9
2018 9
2019 15
2020 19
2021 14
2022 11
2023 10
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Topical Imiquimod for the Treatment of High-Grade Squamous Intraepithelial Lesions of the Cervix: A Randomized Controlled Trial.
Fonseca BO, Possati-Resende JC, Salcedo MP, Schmeler KM, Accorsi GS, Fregnani JHTG, Antoniazzi M, Pantano NP, Santana IVV, Matsushita GM, Dos Reis R. Fonseca BO, et al. Obstet Gynecol. 2021 Jun 1;137(6):1043-1053. doi: 10.1097/AOG.0000000000004384. Obstet Gynecol. 2021. PMID: 33957649 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the histologic response rate of high-grade squamous intraepithelial lesions (HSIL) of the cervix after topical application of 5% imiquimod cream. METHODS: In this phase II trial, women with cervical HSIL (cervical intraepithelial neoplasia [CIN] 2-3) …
OBJECTIVE: To evaluate the histologic response rate of high-grade squamous intraepithelial lesions (HSIL) of the cervix after topical applic …
Imiquimod for anogenital warts in non-immunocompromised adults.
Grillo-Ardila CF, Angel-Müller E, Salazar-Díaz LC, Gaitán HG, Ruiz-Parra AI, Lethaby A. Grillo-Ardila CF, et al. Cochrane Database Syst Rev. 2014 Nov 1;2014(11):CD010389. doi: 10.1002/14651858.CD010389.pub2. Cochrane Database Syst Rev. 2014. PMID: 25362229 Free PMC article. Review.
OBJECTIVES: To assess the effectiveness and safety of imiquimod for the treatment of AGW in non-immunocompromised adults. ...The evidence for many of the outcomes that show imiquimod and patient-applied treatment (podophyllotoxin or podophyllin) confer similar benef …
OBJECTIVES: To assess the effectiveness and safety of imiquimod for the treatment of AGW in non-immunocompromised adults. ...The evid …
Imiquimod for Cervical and Vaginal Intraepithelial Neoplasia: A Systematic Review and Meta-analysis.
Inayama Y, Takamatsu S, Hamanishi J, Mizuno K, Horinouchi N, Yamanoi K, Taki M, Murakami R, Yamaguchi K, Kosaka K, Efthimiou O, Kawakami K, Furukawa TA, Mandai M. Inayama Y, et al. Obstet Gynecol. 2023 Aug 1;142(2):307-318. doi: 10.1097/AOG.0000000000005256. Epub 2023 Jul 5. Obstet Gynecol. 2023. PMID: 37411024 Free article.
We estimated pooled odds ratios (ORs) of imiquimod, compared with placebo or no intervention. We also conducted a meta-analysis of the proportions of patients with adverse events in the imiquimod arms. ...An additional four studies were available for meta-analyses o …
We estimated pooled odds ratios (ORs) of imiquimod, compared with placebo or no intervention. We also conducted a meta-analysis of th …
Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial.
Trutnovsky G, Reich O, Joura EA, Holter M, Ciresa-König A, Widschwendter A, Schauer C, Bogner G, Jan Z, Boandl A, Kalteis MS, Regauer S, Tamussino K. Trutnovsky G, et al. Lancet. 2022 May 7;399(10337):1790-1798. doi: 10.1016/S0140-6736(22)00469-X. Epub 2022 Apr 25. Lancet. 2022. PMID: 35483400 Clinical Trial.
Patients were randomly assigned (1:1) by block randomisation to imiquimod or surgery, and stratified by unifocal or multifocal disease. ...Clinical response to treatment could be assessed in 107 patients (54 in the imiquimod group and 53 in the surgery group), and 9 …
Patients were randomly assigned (1:1) by block randomisation to imiquimod or surgery, and stratified by unifocal or multifocal diseas …
Imiquimod: a review of basal cell carcinoma treatments.
Karve SJ, Feldman SR, Yentzer BA, Pearce DJ, Balkrishnan R. Karve SJ, et al. J Drugs Dermatol. 2008 Nov;7(11):1044-51. J Drugs Dermatol. 2008. PMID: 19110735 Review.
A MEDLINE search of the literature was performed to identify studies published between January 1, 1995 and March 31, 2008 that evaluated imiquimod efficacy, safety, and quality of life in treating BCC. Overall, imiquimod 5% cream was associated with increased clinic …
A MEDLINE search of the literature was performed to identify studies published between January 1, 1995 and March 31, 2008 that evaluated …
Efficacy of imiquimod in the management of lentigo maligna.
Daude M, Dinulescu M, Nguyen JM, Maillard H, Le Duff F, Machet L, Beylot-Barry M, Legoupil D, Wierzbicka-Hainaut E, Bedane C, Leccia MT, Debarbieux S, Meyer N, Monestier S, Bens G, Denis MG, Bossard C, Vergier B, Khammari A, Dréno B. Daude M, et al. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1785-1791. doi: 10.1111/jdv.19141. Epub 2023 May 6. J Eur Acad Dermatol Venereol. 2023. PMID: 37114291 Clinical Trial.
Excision margins of 5-10 mm remain, without international consensus. Several studies have shown that imiquimod, an immunomodulator, induces LM regression. This study investigated the effect of imiquimod versus placebo in neoadjuvant settings. PATIENTS AND METHODS: W …
Excision margins of 5-10 mm remain, without international consensus. Several studies have shown that imiquimod, an immunomodulator, i …
Efficacy and safety of imiquimod 5% cream for basal cell carcinoma: a meta-analysis of randomized controlled trial.
Jia HX, He YL. Jia HX, et al. J Dermatolog Treat. 2020 Dec;31(8):831-838. doi: 10.1080/09546634.2019.1638883. Epub 2019 Jul 22. J Dermatolog Treat. 2020. PMID: 31294669 Review.
Background: We conducted this meta-analysis to compare the efficacy and safety of imiquimod with other treatments in patients with basal cell carcinoma (BCC).Methods: A comprehensive literature search was performed in the database of PubMed, Embase, and Web of Science, foc …
Background: We conducted this meta-analysis to compare the efficacy and safety of imiquimod with other treatments in patients with ba …
The efficacy of topical imiquimod in high-grade cervical intraepithelial neoplasia: A systematic review and meta-analysis.
van de Sande AJM, Kengsakul M, Koeneman MM, Jozwiak M, Gerestein CG, Kruse AJ, van Esch EMG, de Vos van Steenwijk PJ, Muntinga CLP, Bramer WM, van Doorn HC, van Kemenade FJ, van Beekhuizen HJ. van de Sande AJM, et al. Int J Gynaecol Obstet. 2024 Jan;164(1):66-74. doi: 10.1002/ijgo.14953. Epub 2023 Jun 23. Int J Gynaecol Obstet. 2024. PMID: 37350560 Review.
In comparison to imiquimod, surgical treatment had an OR of 14.81(95% CI 6.59-33.27) for histological regression to CIN 1. The hr-HPV clearance rate was 53.4% after imiquimod and 66% after surgical treatment (95% CI 0.62-23.77). CONCLUSIONS: The histological regress …
In comparison to imiquimod, surgical treatment had an OR of 14.81(95% CI 6.59-33.27) for histological regression to CIN 1. The hr-HPV …
Efficacy of 5% imiquimod for the treatment of Vaginal intraepithelial neoplasia-A systematic review of the literature and a meta-analysis.
Tranoulis A, Laios A, Mitsopoulos V, Lutchman-Singh K, Thomakos N. Tranoulis A, et al. Eur J Obstet Gynecol Reprod Biol. 2017 Nov;218:129-136. doi: 10.1016/j.ejogrb.2017.09.020. Epub 2017 Sep 27. Eur J Obstet Gynecol Reprod Biol. 2017. PMID: 28985547 Review.
To date, treatment recommendations vary with no universally accepted standard of care as best treatment modality. Nevertheless, 5% imiquimod appears to be a promising, alternative, non-invasive treatment option. To ascertain the efficacy of 5% imiquimod for the trea …
To date, treatment recommendations vary with no universally accepted standard of care as best treatment modality. Nevertheless, 5% imiqui
Imiquimod for actinic keratosis: systematic review and meta-analysis.
Hadley G, Derry S, Moore RA. Hadley G, et al. J Invest Dermatol. 2006 Jun;126(6):1251-5. doi: 10.1038/sj.jid.5700264. J Invest Dermatol. 2006. PMID: 16557235 Free article. Review.
The proportion of patients with any adverse event, any local adverse event, or any treatment-related adverse event was substantially higher with imiquimod than with vehicle, and numbers needed to harm for one additional adverse event with imiquimod over 12-16 weeks …
The proportion of patients with any adverse event, any local adverse event, or any treatment-related adverse event was substantially higher …
233 results